Cellceutix Prurisol, Kevetrin clinical trials move ahead
The US Food and Drug Administration (FDA) suggested Cellceutix that an application for a 505(b)(2) designation for Prurisol will be an acceptable approach that allows the company to
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).